Promising systemic therapy for renal cell carcinoma

Current Treatment Options in Oncology

Volumn 6, Issue 5, 2005, Pages 357-365

  Cooney, Matthew M ^b   Remick, Scot C ^b   Vogelzang, Nicholas J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; EPOTHILONE DERIVATIVE; ERLOTINIB; ERYTHROPOIETIN; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; IXABEPILONE; LENALIDOMIDE; MESSENGER RNA; OXYGEN; PACLITAXEL; PLACEBO; PLATELET DERIVED GROWTH FACTOR B; PREDNISONE; SORAFENIB; SUNITINIB; THALIDOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERANCE; EPISTAXIS; FATIGUE; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; GENE TARGETING; GENETIC PREDISPOSITION; HEMATURIA; HEREDITY; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTOPENIA; METASTASIS POTENTIAL; MISSENSE MUTATION; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONSENSE MUTATION; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PLASMA HALF LIFE; PROTEIN BINDING; PROTEINURIA; PRURITUS; REVIEW; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VON HIPPEL LINDAU DISEASE;

EID: 28044448529     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0039-5     Document Type: Review

References (44)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. J Clin 2000, 50:7-33.
2. Shapiro JA, Williams MA, Weiss NS: Body mass index and risk of renal cell carcinoma. Epidemiology 1999, 10:188-191.
3. Zambrano NR, Lubensky IA, Merino MJ, et al.: Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol 1999, 62:1246-1258.
4. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced kidney carcinoma. J Clin Oncol 1999, 17:2530-2540.
5. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 1:832-841.
6. Yang JC, Sherry RM, Steinberg SM, et al.: Randomized study of high-dose and low-dose Interleukin-2 in patients with metastastic renal cancer. J Clin Oncol 2003, 21:3127-3132.
7. Ji J, Si L, Fang W, Ling W: Interferon-gamma inhibits in situ expression of PDGF-beta mRNA by smooth muscle cells in injured rabbit arteries after transluminal balloon angioplasty. Clin Med J 2001, 114:139-142.
8. Medical Research Council Collaborators: Interferon-a and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet 1999, 353:14-17.
9. Pyrhonen S, Salminen E, Ruutu M, et al.: Prospective randomized trial of interferon alpha-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999, 17:2859-2867.
10. Flannigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
11. Blankenship C, Naglich JG, Whaley JM, et al.: Alternate choicec of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 1999, 18:1529-1535.
12. Maxwell PPH, Wiesener MS, Chang GW, et al.: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
13. Kamura T, Sato S, Iwai K, et al.: Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000, 97:10430-10435.
14. Cockman ME, Masson N, Mole DR, et al.: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000, 275:25733-25741.
15. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of Bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
16. Drucker BJ, Schwartz L, Marion S, Motzer R: Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma [abstract 720]. Proc ASCO 2002, 21:181a.
17. Dawson NA, Guo C, Zak R, et al.: A phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma [abstract 1623]. Proc ASCO 2003, 22:404.
18. Hidalgo M: Erlotinib: preclinical investigations. Oncology 2003, 17(Suppl 12):11-16.
19. Hainsworth JD, Sosman A, Spigel DR, et al.: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) [abstract 4502]. Proc ASCO 2004, 22:14s.
20. Rosen L, Mulay M, Long J, et al.: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract 765]. Proc ASCO 2003, 22:191.
21. Motzer RJ, Rini BI, Michaelson MD, et al.: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial [abstract 4500]. Proc ASCO 2004, 22:14s.
22. Motzer RJ, Berg W, Ginsberg M, et al.: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002, 20:302-306.
23. Hernberg M, Virkkunen P, Bono P, et al.: Interferon alpha-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 2003, 21:3770-3776.
24. Olenki T, Malhi S, Mekhail T, et al.: Phase I trial of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC) [abstract 1554]. Proc ASCO 2003, 22:387.
25. Dredge K, Marriott JB, MacDonald CD, et al.: Novel thalidomide analogues display anti-angiogenic activity independent of immunomodulatory effects. Brit J Cancer 2002, 87:1166-1172.
26. Richardson PG, Schlossman RL, Weller E, et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
27. Liu Y, Tohnya TM, Figg WD, et al.: Phase I study of CC-5013 (Revimid), a thalidomide derivative in patients with refractory metastatic cancer [abstract 927]. Proc ASCO 2003, 22:231.
28. Wu A, Scheffler R: Multiple-dose pharmacokinetics and safety of CC-5013 in 15 multiple myeloma patients [abstract 2056]. Proc ASCO 2004, 22:14s.
29. Chapa P, Rawat A, Amato RJ: Phase II study of CC-5013 in patients (pts) with renal cell cancer (RCC) [abstract 4761]. Proc ASCO 2004, 22:14s.
30. Chong H, Vikis HG, Guan KL: Mechanisms of regulating Raf kinase family. Cell Signal 2003, 15:463-469.
31. Shawver LK: Tyrosine kinase inhibitors: from the emergence of targets to their clinical development. Proc ASCO 1999, 29:45.
32. Davies H, Bignell GR, Cox Q et al.: Mutations of B-raf in human cancer. Nature 2002, 417:949-954.
33. Hotte SJ, Hirte HW: BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002, 8:2249-2253.
34. Flaherty KT, Lee RJ, Humphries R, et al.: Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P) [abstract 2854]. Proc ASCO 2003, 22:710.
35. Siu L, Awada A, Takimoto CH, et al.: Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors [abstract 828]. Proc ASCO 2003, 22:207.
36. Strumberg D, Awada A, Piccart M, et al.: Final report of the phase I clinical program of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors [abstract 813]. Proc ASCO 2003, 22:203.
37. Wong K-K, Eder JP, Clark J, et al.: Final results of a phase I study to determine the safety, maximum tolerated dose, pharmacokinetics and pharmacodynamics of BAY 43-9006 in repeated cycles of 1 week on/1 week off in patients with advanced, refractory solid tumors [abstract 976]. Proc ASCO 2003, 22:244.
38. Ratain MI, Flaherty KT, Stadler WM, et al.: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [abstract 4501]. Proc ASCO 2004, 23:381.
39. Lee FY, Borzilleri R, Fairchild CR, et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001, 7:1429-1437.
40. Mani S, McDaid H, Hamilton A, et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004, 10:1289-1298.
41. Burris HI, Awada A, Jones S, et al.: Phase I study of the novel epothilone BMS-247550 administered weekly in patients with advanced malignancies [abstract 412]. Proc ASCO 2002, 21:104a.
42. Plummer R, Molife R, Verrill M, et al.: Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies [abstract 2125]. Proc ASCO 2002, 21:78b.
43. Mani S, McDaid H, Hamilton A, et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004, 10:1289-1298.
44. Zhuang SH, Menefee M, Kotz H, et al.: A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer [abstract 4550]. Proc ASCO 2004, 22:14s.